A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Post time 2026-8-14 14:32:46

journal：New England Journal of Medicine

Authors：Stephen A. Harrison; Pierre Bedossa; Cynthia D. Guy; Jrn M. Schattenberg; Rohit Loomba; Rebecca Taub; Dominic Labriola; Sam E. Moussa; Guy W. Neff; Mary E. Rinella; Quentin M. Anstee; Manal F. Abdelmalek; Zobair Younossi; Seth J. Baum; Sven Francque; Michael R. Charlton; Philip N. Newsome; Nicolas Lanthier; Ingolf Schiefke; Alessandra Mangia; Juan M. Pericàs; Rashmee Patil; Arun J. Sanyal; Mazen Noureddin; Meena B. Bansal; Naim Alkhouri; Laurent Castera; Madhavi Rudraraju; Vlad Ratziu

Published date：2024-2-8

DOI：10.1056/nejmoa2309000

PDF link：http://www.nejm.org/doi/pdf/10.1056/NEJMoa2309000

Article link：https://doi.org/10.1056/nejmoa2309000

Article Source：Massachusetts Medical Society。

Remark：

Post time 2026-8-14 14:32:47

: This post has been completed
Completed attachments will be deleted within 24 hours.

[NEJM] A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[NEJM] A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[NEJM] A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis